fine-tune receptor activity, increasing specificity and signaling bias. This unique focus on allosteric modulation opens new avenues for drug discovery and development, targeting a wide range of therapeutics areas, including neurology, oncology, and metabolic disorders.

Founded by a group of dedicated co-founders with expertise in computational biology, biophysics, and bioinformatics, P42med has successfully bootstrapped its operations since its inception. The team has developed a robust in silico pipeline and demonstrated promising activity for both allosteric and orthosteric modulators of GPCRs, positioning P42med at the forefront of innovative drug design strategies. The startup is exploring various routes of development, such as pursuing experimental results in the form of drug candidate libraries or focusing on further refining its unique in silico approach.

P42med's vision is to revolutionize the drug discovery process through computational techniques, ultimately leading to the development of novel therapies that improve and extend people's lives. By bridging the gap between fundamental biomedical research and the pharmaceutical industry, P42med aims to accelerate the translation of groundbreaking research into life-changing medicines.